Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia.
about
Polyphenols: a Promising Nutritional Approach to Prevent or Reduce the Progression of Prehypertension.Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trialClinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet.Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trialGenetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine.Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine) in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-Controlled StudyNutraceuticals: Definition and Epidemiological Rationale for Their Use in Clinical Practice.Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study.Vitamin D, parathyroid hormone and cardiovascular risk: the good, the bad and the ugly.The Age of Nutraceuticals: Exploring New Therapeutic Targets.Nutraceuticals for blood pressure control in patients with high-normal or grade 1 hypertension.Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study.Wild Plant-Based Functional Foods, Drugs, and NutraceuticalsNutraceuticals for Blood Pressure Control in Patients with High-Normal or Grade 1 Hypertension
P2860
Q30251508-AEAADCAD-1CB9-48A8-936E-14B76C61F316Q33988933-AF030360-AB18-41EA-ADB5-C575793004B1Q35151507-13C782D9-6266-4545-B132-626AC4DE6836Q35708669-5F661A93-E87D-4BC9-A73C-0972BF56EFC4Q35970280-69DEC5C4-6EE4-403E-92FE-A283F3BCF649Q36278238-5F10A5F7-C0B2-40EA-802A-4897EE3172ECQ38451985-EA9A6720-92DA-4502-BAC9-25CA653D90FDQ38680653-05B9FE51-60DD-4157-9BD2-EEAB3866FD22Q47291131-3FE9417A-C00A-4B9D-A0E6-99D328EB3957Q48244164-A6A54E4F-631C-41BF-B089-F231DBC3FE17Q50503247-E494AD4D-7489-4CDC-A356-07B29FA45C10Q51490249-CD264297-3250-4275-97B5-71E569945FC2Q57614934-A09BD24D-C16A-49CB-BF95-728FA936E733Q59184118-BDD530FE-F5EA-41F1-AAC4-99FDA0D5EDEC
P2860
Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Effects of nutraceuticals on p ...... individuals with dyslipidemia.
@en
Effects of nutraceuticals on p ...... individuals with dyslipidemia.
@nl
type
label
Effects of nutraceuticals on p ...... individuals with dyslipidemia.
@en
Effects of nutraceuticals on p ...... individuals with dyslipidemia.
@nl
prefLabel
Effects of nutraceuticals on p ...... individuals with dyslipidemia.
@en
Effects of nutraceuticals on p ...... individuals with dyslipidemia.
@nl
P2093
P1476
Effects of nutraceuticals on p ...... individuals with dyslipidemia.
@en
P2093
Bruno Trimarco
Nicola De Luca
Raffaele Izzo
Renata Giudice
Valentina Trimarco
P304
P356
10.1097/HJH.0B013E3283395208
P577
2010-07-01T00:00:00Z